ADRB2 and neoplasm: Moreover, recent research has shown that catecholamine significantly increased the proliferation, invasion, and viability of tumor cells in vivo, and this effect could be inhibited by an ADRB2 antagonist through suppression of the ERK1/2-JNK-MAPK pathway and transcription factors [20].